Form 4: EcoR1 Capital Increases Stake in AnaptysBio Through Multiple Share Purchases

EcoR1 Capital, along with Oleg Nodelman, has increased its indirect holdings in AnaptysBio through a series of open market purchases of common stock.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman, has reported several transactions involving the purchase of AnaptysBio common stock.
• These transactions occurred between December 30, 2024, and January 2, 2025.
• The purchases were made by EcoR1 Capital Fund Qualified L.P., a fund managed by EcoR1 Capital.
• A total of 85,098 shares were acquired across the three transactions at weighted average prices ranging from $12.9182 to $12.9506 per share.
• Following these transactions, the total indirect holdings of EcoR1 Capital in AnaptysBio common stock increased to 7,880,094 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it shows a major shareholder increasing their stake, which is generally a good sign. However, it is a routine transaction and not a major event.

Positives

• EcoR1 Capital's increased investment signals confidence in AnaptysBio's future prospects.
• The purchases demonstrate a commitment from a major shareholder.

Risks

• The document does not explicitly state any risks, but it is important to note that market conditions and company performance can impact the value of these holdings.

Management Comments

• Oleg Nodelman, as manager of EcoR1 Capital, signed the form, indicating his awareness and approval of the transactions.

Industry Context

This type of transaction is common in the biotech industry, where institutional investors often adjust their holdings based on their assessment of a company's prospects. It is a routine disclosure required by the SEC.

Comparison to Industry Standards

• The share purchases are typical for institutional investors and are not unusual in the biotech sector.
• Similar transactions are regularly reported by other investment firms in the industry, such as Baker Bros. Advisors and OrbiMed Advisors, who also actively manage their positions in various biotech companies.
• The reported prices are within the typical range for open market transactions, and the volume of shares purchased is not unusually high or low for a fund of this size.

Stakeholder Impact

• The increased stake by EcoR1 Capital could be viewed positively by shareholders, potentially increasing confidence in the company.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

AnaptysBio, EcoR1 Capital, Oleg Nodelman, share purchase, common stock, insider trading, beneficial ownership